The B7 family member B7-H3 preferentially down-regulates T helper type 1–mediated immune responses
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
We investigated the in vivo function of the B7 family member B7-H3 (also known as B7RP-2) by gene targeting. B7-H3 inhibited T cell proliferation mediated by antibody to T cell receptor or allogeneic antigen-presenting cells. B7-H3-deficient mice developed more severe airway inflammation than did wild-type mice in conditions in which T helper cells differentiated toward type 1 (T(H)1) rather than type 2 (T(H)2). B7-H3 expression was consistently enhanced by interferon-gamma but suppressed by interleukin 4 in dendritic cells. B7-H3-deficient mice developed experimental autoimmune encephalomyelitis several days earlier than their wild-type littermates, and accumulated higher concentrations of autoantibodies to DNA. Thus, B7-H3 is a negative regulator that preferentially affects T(H)1 responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, CD276 (B7-H3), known to augment Tregs and inhibit T cell responses (Costa et al., 2018, Prasad et al., 2004, Suh et al., 2003), was expressed most prominently on CAFs and TSKs.”
From Multimodal Analysis of Composition and Spatial Architecture in Human Squamous Cell Carcinoma (2020) · cites this paper as Suh et al., 2003
In the citing paper
“B7H3 has been shown to promote tumor metastasis and invasion via suppression of both CD8+ and CD4 + T cell proliferation and activity86,87.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [87]
Citations
Cites
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., & Steinman, R. M. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.6.1693 · Cited by 3,738
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Self-citationNishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749 · cited 1×
“The idea that PD-1 has an immune inhibitory function is supported by the phenotype of PD-1-deficient mice, which develop lupus-like diseases or autoimmune dilated cardiomyopath”
BackgroundCD28/B7 SYSTEM OF T CELL COSTIMULATION
Lenschow, D. J., Walunas, T. L., & Bluestone, J. A. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.233 · Cited by 2,717 · cited 1×
“gif" NDATA ITEM> ]> An optimal T cell response is achieved by a combination of signals delivered through the antigen-specific T cell receptor (TCR) and accessory signals that are either stimulatory or inhibitor”
BackgroundDong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Cited by
Items 301–400 of 573
Si, S., Wang, L., Cao, H., Xu, Y., & Zhan, Q. (2022) · BMC Cancer · doi:10.1186/s12885-022-09294-w · Cited by 27
“B7-H3 expression shows no notable correlation with major TIICs, including CD3 + , CD8 + and CD20 + TIICs in small cell lung cancer [32], whereas B7-H3 expression is positively correlated with the abundance of CD45 + and CD8 + TIICs in non-smallcell lung cancer [33].”
BackgroundPicarda, É., Galbo, P. M., Zong, H., Rajan, M. R., Wallenius, V., Zheng, D., Börgeson, E., Singh, R., Pessin, J. E., & Zang, X. (2022) · Science Advances · doi:10.1126/sciadv.abm7012 · Cited by 29
“Animals and animal care B7-H3 KO mice were previously generated ( 66 ) and had been back-crossed at least 12 generations onto the C57Bl/6 background.”
UBR5 targets tumor suppressor CDC73 proteolytically to promote aggressive breast cancer
Xiang, G., Wang, S., Chen, L., Song, M. L., Song, X., Wang, H., Zhou, P., Ma, X., & Yu, J. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04914-6 · Cited by 31
Jiang, J., Jiang, J., Liu, C., Zhang, G., Gao, L., Chen, Y., Zhu, R., Wang, T., Wang, F., Zhang, X., et al. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9800-2 · Cited by 27
“However, its inhibitory properties, including impairment of Th1 responses and protection from natural killer cell mediated lysis, have recently been reported [10–12].”
BackgroundResultCoinhibitory T-Cell Signaling in Islet Allograft Rejection and Tolerance
Truong, W., Hancock, W. W., Anderson, C. C., Merani, S., & Shapiro, A. M. J. (2006) · Cell Transplantation · doi:10.3727/000000006783982160 · Cited by 30
Moyo, N. A., Marchi, E., & Steinbach, F. (2013) · Immunology · doi:10.1111/imm.12094 · Cited by 30
Lee, C.-C., Ho, K., Huang, T., Shih, C.-M., Hsu, S.-Y., Liu, A.-J., & Chen, K. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119438 · Cited by 28
Expression, regulation and clinical significance of B7-H3 on neutrophils in human gastric cancer
Li, Z., Wang, J., Chen, G., Shan, Z., Wang, T., Shen, Y., Chen, J., Yan, Z., Peng, L., Mao, F.-Y., et al. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108753 · Cited by 27
Vuletić, A. M., Martinović, K. M., Miletić, N. T., Zoidakis, J., Castellví-Bel, S., & Cavic, M. R. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.750022 · Cited by 34
Dendritic cell–regulatory T‐cell interactions control self‐directed immunity
Lange, C. M., Dürr, M., Doster, H., Melms, A., & Bischof, F. (2007) · Immunology and Cell Biology · doi:10.1038/sj.icb.7100088 · Cited by 31
Gorczynski, R. M. (2006) · Transplantation · doi:10.1097/01.tp.0000214984.65520.50 · Cited by 26
Inhibitory costimulation and anti-tumor immunity
Martín‐Orozco, N., & Dong, C. (2007) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2007.06.003 · Cited by 26
“Interestingly, deficiency in B7-H3 did not affect Th2 responses or eosinophilia in an asthma model [45].”
BackgroundLee, D., Ryu, H. S., Jin, M., Lee, K.-H., Suh, K. J., Youk, J., Kim, J. Y., Min, A., Lee, H., Moon, H., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0511-9 · Cited by 28
Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers
Zhou, G., Boor, P. P. C., Bruno, M. J., Sprengers, D., & Kwekkeboom, J. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01453-3 · Cited by 33
Xu, J., Huang, B., Xiong, P., Feng, W., Xu, Y. X., Fang, M., Zheng, F., & Gong, F. (2006) · PubMed · Cited by 25
Targeting Costimulatory Pathways for Tumor Immunotherapy
Ward, R. C., & Kaufman, H. L. (2007) · International Reviews of Immunology · doi:10.1080/08830180701365941 · Cited by 27
Role of B7H3/IL-33 Signaling in Pulmonary Fibrosis–induced Profibrogenic Alterations in Bone Marrow
Nakashima, T., Liu, T., Hu, B., Wu, Z. B., Ullenbruch, M. R., Omori, K., Ding, L., Hattori, N., & Phan, S. H. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201808-1560oc · Cited by 26
“Immunoregulation by B7H3 is in part mediated by an enhancing effect on Thelper cell type 2 (Th2) immune response with suppression of Th1 response, thus resulting in a net Th2 polarization (17, 18, 23).”
BackgroundTissue-Expressed B7x Affects the Immune Response to and Outcome of Lethal Pulmonary Infection
Hofmeyer, K. A., Scandiuzzi, L., Ghosh, K., Pirofski, L., & Zang, X. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200701 · Cited by 26
“B7x and B7-H3–deficient (B7-H3) mice on the C57BL/6 background were previously described (6, 23).”
MethodYoon, B. R., Chung, Y., Yoo, S.-J., Kawara, K., Kim, J., Yoo, I. S., Park, C., Kang, S. W., & Lee, W. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.680298 · Cited by 25
“An optimal T cell response is accomplished through the integration of signals downstream of the antigen-specific T cell receptor (TCR) and from a set of auxiliary signals, which can be either stimulatory or inhibitory, generated through co-signaling molecules (7, 8).”
BackgroundInfluentialChen, X., Li, Y., Blankson, S., Liu, M., Huang, D., Redmond, H. P., Huang, J., Wang, J. H., & Wang, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171146 · Cited by 24
Anticancer natural products targeting immune checkpoint protein network
Chun, K., Kim, D., Raut, P. K., & Surh, Y. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.11.006 · Cited by 26
B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer?
Malapelle, U., Parente, P., Pepe, F., Micco, M. C. D., Russo, A., Clemente, C., Graziano, P., & Rossi, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416077 · Cited by 24
“Accordingly, the heterogeneous expression in human tissue of this promising biomarker suggests that post-transcriptional modifications regulate protein expression levels [18].”
BackgroundSabado, R. L., Meseck, M. L., & Bhardwaj, N. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3387-7_44 · Cited by 24
Soluble B7-H3 elevations in hospitalized children with Mycoplasma pneumoniae pneumonia
Chen, Z., Zhang, G., Wang, Y., Yan, Y., Zhou, W., Zhu, C., Wang, J., & Ji, W. (2013) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2013.09.006 · Cited by 23
“B7-H3, a newly discovered member of the B7 superfamily, plays an important role in the regulation of both innate and Ag-specific T cell-mediated immune responses (Chapoval et al., 2001; Chen et al., 2009; Suh et al., 2003; Zhang et al., 2010).”
BackgroundGu, W., Zhang, X., Yan, Y., Wang, Y., Huang, L., Wang, M., Shao, X., Chen, Z., & Ji, W. (2017) · Scientific Reports · doi:10.1038/srep40398 · Cited by 23
Tissue Biomarkers for Prostate Cancer Radiation Therapy
Tran, P. T., Hales, R. K., Zeng, J., Aziz, K., Salih, T., Gajula, R., Chettiar, S. T., Gandhi, N. S., Wild, A. T., Kumar, R., et al. (2012) · Current Molecular Medicine · doi:10.2174/156652412800792589 · Cited by 22
“B7-H3 functions are likely context dependent and can involve inhibition or stimulation of the immune response [192-195], but overexpression of B7-H3 has been correlated to worse clinical outcomes in prostate cancer [196].”
BackgroundSugita, S., Futatsugi, Y., Ishida, M., Edo, A., & Takahashi, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186507 · Cited by 23
Alternative Checkpoints as Targets for Immunotherapy
Pant, A., Medikonda, R. T., & Lim, M. K. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00983-y · Cited by 25
Wang, J., Chen, X., Xie, C., Sun, M., Hu, C., Zhang, Z., Luan, L., Zhou, J., Zhou, J., Zhu, X., et al. (2021) · Molecular Biotechnology · doi:10.1007/s12033-021-00348-1 · Cited by 22
Waschbisch, A., Wintterle, S., Lochmüller, H., Walter, M. C., Wischhusen, J., Kieseier, B. C., & Wiendl, H. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23997 · Cited by 22
Overexpression of B7-H3 Is Associated With Poor Prognosis in Laryngeal Cancer
Li, Y., Cai, Q., Shen, X., Chen, X., & Guan, Z. Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.759528 · Cited by 21
“Chapoval et al. (3) reported that B7-H3 promoted proliferation of both CD4+ and CD8+ T-cells, and enhanced function of the cytotoxic T-cell (CTL).”
ResultInfluentialEvaluation of B7-H3 Targeted Immunotherapy in a 3D Organoid Model of Craniopharyngioma
Tang, M., Chen, C., Wang, G., Wang, Y., Zhang, Z., Li, H., Lu, Q., Wang, Z., Zhao, S., Chen, Y., et al. (2022) · Biomolecules · doi:10.3390/biom12121744 · Cited by 22
Davis, R. J., Ferris, R. L., & Schmitt, N. C. (2016) · Cancers of the Head & Neck · doi:10.1186/s41199-016-0013-x · Cited by 25
“Initially identified as a co-stimulatory receptor of T cell function [63], B7-H3 has since been described as a coinhibitory checkpoint expressed in a variety of tumor types [64, 65].”
BackgroundChen, X., Meng, X., Foley, N. M., Shi, X., Liu, M., Chai, Y., Li, Y., Redmond, H. P., Wang, J., & Wang, J. H. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.07.002 · Cited by 21
B7-H3 and its role in bone cancers
He, L., & Li, Z. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.04.012 · Cited by 24
The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer
Lin, C., Hadfield, M. J., Santopietro, A., Lagos, G., Cheng, L., El-Deiry, W. S., Aggarwal, R., Mega, A., Hyams, E., & Carneiro, B. A. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01131-0 · Cited by 20
Tumor immune checkpoints and their associated inhibitors
Gao, Z., Ling, X., Shi, C., Wang, Y., & Lin, A. (2022) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2200195 · Cited by 21
“…of TCR sig‐ naling (Chapoval et al., 2001; Zhang et al., 2004); however, a growing body of evidence suggests that B7-H3 plays a negative regulatory role in antitumor immunity (Chapoval et al., 2001; Suh et al., 2003; Zhang et al., 2004; Mahnke et al., 2007; Leitner et al., 2009; Lee et al., 2017).”
BackgroundDai, L., Guo, X., Xing, Z., Tao, Y., Liang, W., Shi, Z., Hu, W., Zhou, S., & Wang, X. (2023) · BMC Cancer · doi:10.1186/s12885-023-10575-1 · Cited by 20
Liang, J., Liu, Z., Pei, T., Xiao, Y., Zhou, L., Tang, Y., Zhou, C., Wu, K., Zhang, F., Zhang, F., et al. (2020) · Disease Markers · doi:10.1155/2020/5354825 · Cited by 20
“Negative regulation by CD276 of the immune cell response, such as T cells and NK cells, has recently been reported [23, 24].”
Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3
Li, N., Spetz, M. R., Li, D., & Ho, M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107892 · Cited by 22
B7-H3: another molecule marker for Mo-DCs?
Zhang, G., Dong, Q.-M., Xu, Y., Yu, G., & Zhang, X. (2005) · PubMed · Cited by 20
The characteristic expression of B7-associated proteins in Langerhans cell sarcoma
Li, H., Wang, C., Guo, G., Gao, C., Wu, Y., & Chen, Y. (2012) · Acta Histochemica · doi:10.1016/j.acthis.2011.12.010 · Cited by 20
Calabrò, L., Sigalotti, L., Fonsatti, E., Bertocci, E., Giacomo, A. M. D., Danielli, R., Cutaia, O., Colizzi, F., Covre, A., Mutti, L., et al. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22600 · Cited by 21
“…cells, and antigen-presenting cells (APC), and it is up-regulated during the differentiation of monocytes to dendritic cells (DC), and following the interaction between DC and regulatory T cells (Tregs) (Chapoval et al., 2001; Suh et al., 2003; Steinberger et al., 2004; Zhang and Allison, 2007).”
BackgroundZhang, L., Jin, Y., Xia, P., Lin, J., Ma, J., Li, T., Liu, Z., Xiang, H., Chen, C., Xu, Z., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.4284 · Cited by 20
Crosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities
Ren, X., Li, Y., Nishimura, C., & Zang, X. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.08.009 · Cited by 20
Canine Melanoma Immunology and Immunotherapy: Relevance of Translational Research
Tarone, L., Giacobino, D., Camerino, M., Ferrone, S., Buracco, P., Cavallo, F., & Riccardo, F. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.803093 · Cited by 21
“B7-H3 is a type I transmembrane protein member of the B7-superfamily (60).”
BackgroundThe tumor microenvironment and immune targeting therapy in pediatric renal tumors
Hont, A. B., Dumont, B., Sutton, K. S., Anderson, J., Kentsis, A., Drost, J., Hong, A. L., & Verschuur, A. C. (2022) · Pediatric Blood & Cancer · doi:10.1002/pbc.30110 · Cited by 19
Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities
Li, H.-Y., Chen, Y., Deng, X., Li, H., Tan, J., Liu, G., Zheng, Y., Pei, M., Peng, K.-T., Yue, L.-L., et al. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01118-2 · Cited by 23
Fan, T. (2026) · American Journal of Translational Research · doi:10.62347/lasv4520 · Cited by 19
Xu, L., Zhang, G., Zhou, Y., Chen, Y., Xu, W., Wu, S., & Zhang, X. (2011) · Immunobiology · doi:10.1016/j.imbio.2011.05.013 · Cited by 21
The interaction of MMP-2/B7-H3 in human osteoporosis
Feng, P., Zhang, H., Zhang, Z., Dai, X., Mao, T., Fan, Y., Xie, X., Wen, H., Yu, P., Hu, Y., et al. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.11.009 · Cited by 20
New developments in immunotherapy for pediatric solid tumors
Schultz, L. M., Majzner, R. G., Davis, K. L., & Mackall, C. L. (2017) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000564 · Cited by 20
Modulation of Immune Response by B7 Family Molecules in Tumor Microenvironments
Flies, D. B., & Chen, L. (2006) · Immunological Investigations · doi:10.1080/08820130600755017 · Cited by 22
Wespiser, M., Gille, R., & Pérol, M. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2512566 · Cited by 18
Genome-scale CRISPR–Cas9 screen reveals novel regulators of B7-H3 in tumor cells
Zhao, S., Wang, Y., Yang, N., Mu, M., Wu, Z., Li, H., Tang, X., Zhong, K., Zhang, Z., Huang, C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004875 · Cited by 19
Wang, F., Daylan, A. E. C., Deng, L., Yang, J., Sharma, J. N., Su, C. T., Li, S., Zang, X., Halmos, B., Borczuk, A., et al. (2023) · Cancers · doi:10.3390/cancers15133372 · Cited by 22
Hub gene of disulfidptosis-related immune checkpoints in breast cancer
Wang, Y., Deng, Y., Xie, H., & Cao, S. (2023) · Medical Oncology · doi:10.1007/s12032-023-02073-y · Cited by 20
“CD276 is both a T cell stimulatory protein [24] and a suppressor of T cell cytotoxicity allowing tumor proliferation and metastasis [25, 26].”
BackgroundImmune checkpoint pathways in glioblastoma: a diverse and evolving landscape
Inocencio, J. F., Mitrasinovic, S., Asad, M., Parney, I. F., Zang, X., & Himes, B. T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1424396 · Cited by 23
Baranzini, S. E. (2006) · Autoimmunity · doi:10.1080/08916930601061686 · Cited by 18
“[53] Suh WK, Gajewska BU, Okada H, Gronski MA, Bertram”
BackgroundGuo, G., Shang, Y., GuoYan, Z., Bao, X., Shiwei, X., & Chen, Y. (2011) · Clinical Rheumatology · doi:10.1007/s10067-011-1815-1 · Cited by 18
“The transcription of B7-H3 mRNA has been found in lymphoid and nonlymphoid organs, while its protein is induced on activated DCs and monocytes [20].”
BackgroundCharacterization of B7S3 as a Novel Negative Regulator of T Cells
Yang, Y., Liu, X. K., Nguyen, T. D., Bishop, C., Graf, D., & Dong, C. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.6.3661 · Cited by 18
“Recent studies indicated mouse B7-H3 as a negative regulator of T cell activation and autoimmune responses (11, 12).”
BackgroundImmunological considerations for cell therapy using human embryonic stem cell derivatives
Drukker, M. (2008) · StemBook · doi:10.3824/stembook.1.14.1 · Cited by 19
“Other molecules involved in co-stimulation of T cells include the adhesion molecules intercellular adhesion molecule (ICAM) -1 and -3 as well as the recently identified members of the B7 family (B7-H1, -H2 and -H3; Suh et al., 2003).”
BackgroundImmune Checkpoints in Pediatric Solid Tumors: Targetable Pathways for Advanced Therapeutic Purposes
Cocco, C., Morandi, F., & Airoldi, I. (2021) · Cells · doi:10.3390/cells10040927 · Cited by 18
“discovered [145], making B7-H3 an interesting target for new immunotherapeutic treatments.”
BackgroundMultiplexed digital spatial profiling of invasive breast tumors from Black and White women
Omilian, A. R., Sheng, H., Hong, C., Bandera, E. V., Khoury, T., Ambrosone, C. B., & Yao, S. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13017 · Cited by 19
Expression of B7-H3 Correlates with PD-L1 and Poor Prognosis in Patients with Cervical Cancer
Zhang, Q., Zong, L., Zhang, H., Xie, W., Yang, F., Sun, W., Cui, B., & Zhang, Y. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s318082 · Cited by 18
“Finally, the criteria for B7-H3 positivity have not been defined, and the cut-off point we used to stratify positive versus negative expression was based on a previous publication describing a prostate cancer study.(6) Additional studies from independent cervical cancer cohorts will be required to determine the optima…”
MethodInfluentialA Novel Anti-B7-H3 × Anti-CD3 Bispecific Antibody with Potent Antitumor Activity
Feng, Y., Xie, K., Yin, Y., Li, B., Pi, C., Xu, X., Huang, T., Zhang, J., Wang, B., Gu, H., et al. (2022) · Life · doi:10.3390/life12020157 · Cited by 21
Kallinich, T., Beier, K. C., Gelfand, E. W., Kroczek, R. A., & Hamelmann, E. H. (2005) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2005.02369.x · Cited by 22
Zheng, X., Xiao, Z. X., Hu, L., Fang, X., Luo, L., & Chen, L. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1623-0 · Cited by 17
Ahangar, N. K., Hemmat, N., Khalaj‐Kondori, M., Shadbad, M. A., Sabaie, H., Mokhtarzadeh, A., Alizadeh, N., Derakhshani, A., Baghbanzadeh, A., Dolatkhah, K., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052652 · Cited by 16
Co-signals in organ transplantation
Dürrbach, A., François, H., Jacquet, A., Beaudreuil, S., & Charpentier, B. (2010) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e32833c1369 · Cited by 16
Wei, X., Zhang, G., Yuan, H., Ding, X., Li, S., Zhang, X., & Hou, J. (2010) · The Journal of Urology · doi:10.1016/j.juro.2010.09.104 · Cited by 17
Dendritic cells in the skin – potential use for melanoma treatment
Marsafy, S. E., Bagot, M., Bensussan, A., & Mauviel, A. (2008) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2008.00532.x · Cited by 16
“These molecules are members of programmed death ligand family (PDL) (Kryczek et al., 2006b; Mahnke et al., 2007b) that inter- fere with Th1 cell response and induction of immune tolerance (Kryczek et al., 2006a; Suh et al., 2003).”
BackgroundNew battlefields for costimulation
Martín‐Orozco, N., & Dong, C. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060219 · Cited by 16
“In addition, the new B7 family ligands B7H3 (4, 5) and B7-H4 (also known as B7S1 or B7x) (6–8) have been shown to inhibit T cell activation, but their receptors on T cells are not yet known.”
BackgroundChen, X., Bai, Y., Cui, W., Wang, Z., Zhang, G., Xu, Y., Zhu, X., Li, Y., & Wang, J. H. (2012) · Journal of Molecular Neuroscience · doi:10.1007/s12031-012-9885-3 · Cited by 15
Kanayama, T., Miyachi, M., Sugimoto, Y., Yagyu, S., Kikuchi, K., Tsuchiya, K., Iehara, T., & Hosoi, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-98322-z · Cited by 16
Zhao, B., Huang, Z., Zhu, X., Cai, H., Huang, Y., Zhang, X., Zhang, Z., Lu, H., An, C., Niu, L., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.819236 · Cited by 15
“Many studies have shown that B7-H3 predominantly acts as a molecular co-inhibitor at tumor sites to generate an immunosuppressive microenvironment (Suh et al., 2003; Zhang et al., 2018).”
BackgroundLina, T. T., Gonzalez, J., Pinchuk, I. V., Beswick, E. J., & Reyes, V. E. (2019) · Clinical Oncology and Research · doi:10.31487/j.cor.2019.05.05 · Cited by 15
“In contrast, B7-H3 has been reported to impair T-helper (Th)1 cell responses and inhibit cytokine production [22].”
BackgroundGeneral Principles of Tumor Immunotherapy: Basic and Clinical Applications of Tumor Immunology
Kaufman, H. L., & Wolchok, J. D. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6087-8 · Cited by 17
Emerging immunotherapy targets in lung cancer
Zhu, H., Feng, Y. Y., & Hu, X. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001082 · Cited by 16
“B7-H3 has been shown to play an inhibitory role on the activities of CD4+ and CD8+ T cells and reduces the production of interleukin (IL)-2 and IFNg.”
BackgroundB7-H3 on breast cancer cell MCF7 inhibits IFN-γ release from tumour-infiltrating T cells
Shao, L., Yu, Q., Xia, R., Zhang, J., Gu, S., Yu, D., & Zhuang, Z. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153461 · Cited by 15
Mapping of Char10, a novel malaria susceptibility locus on mouse chromosome 9
Min‐Oo, G., Willemetz, A., Tam, M., Canonne‐Hergaux, F., Stevenson, M. M., & Gros, P. (2009) · Genes and Immunity · doi:10.1038/gene.2009.78 · Cited by 18
Geerdes, E. E., Sideras, K., Aziz, M. H., van Eijck, C. H. J., Bruno, M. J., Sprengers, D., Boor, P. P. C., & Kwekkeboom, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.615691 · Cited by 14
Chen, S., Zhan, S., Ding, S., Zhang, Q., Xuan, H., Zhang, X., & Cao, L. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05408-4 · Cited by 14
“Initially thought to be a T cell-stimulating protein, recent studies suggested that B7-H3 functions as a co-inhibitory signal, inhibiting T cell activation and promoting tumor aggressiveness and proliferation (Suh et al. 2003; Prasad et al. 2004).”
BackgroundB7-H3 in glioblastoma and beyond: significance and therapeutic strategies
Babič, D., Jovčevska, I., & Zottel, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1495283 · Cited by 16
Mifepristone inhibited the expression of B7-H2, B7-H3, B7-H4 and PD-L2 in adenomyosis
Qin, X., Sun, W., Wang, C., Li, M., Ζhao, X., Li, C., & Zhang, H. (2021) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-021-00800-6 · Cited by 13
B7-H3 regulates anti-tumor immunity and promotes tumor development in colorectal cancer
Zhang, H., Zhu, M., Zhao, A., Shi, T., & Xi, Q. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189031 · Cited by 15
Costimulation Blockade in Transplantation
Yeung, M. Y., Grimmig, T., & Sayegh, M. H. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9717-3_10 · Cited by 13
Pereira, N. Z., Branco, A. C. C. C., Manfrere, K. C. G., de Lima, J. F., Yoshikawa, F. S. Y., Milanez, H. M. B. P. M., Pereira, N. V., Sotto, M. N., Duarte, A. J. D. S., & Sato, M. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01822 · Cited by 13
“Next, we analyzed the expression of B7-H3, a negative regulator of Th1 responses that inhibits the activity of major transcriptional factors including nuclear factor of activated T cells (21), and HLA-G.”
MethodZhou, S., Hong, M., Zhao, D., Li, W., Yuan, X., Wang, Y.-H., Li, H., Yang, Y., Jin, T., & Pan, J. (2025) · Advanced Science · doi:10.1002/advs.202415577 · Cited by 12
Tissue biomarkers of immune checkpoint inhibitor therapy
Davoudi, F., Moradi, A., Sadeghirad, H., & Kulasinghe, A. (2024) · Immunology and Cell Biology · doi:10.1111/imcb.12723 · Cited by 15
B7-H3 in acute myeloid leukemia: From prognostic biomarker to immunotherapeutic target
Tan, X., & Zhao, X. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003099 · Cited by 12
DeSantes, K. B., McDowell, K. A., Sondel, P. M., Hutson, P. R., Kaplan, R. N., Park, J. R., Hegde, M. G., Mackall, C. L., & Maris, J. M. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0293 · Cited by 18
“Most published data support an inhibitory role for B7-H3 on T-cell and NK cell function (16–22).”
B7-H3 promoted proliferation of mouse spermatogonial stem cellsviathe PI3K signaling pathway
Wei, X., Li, K., Zhang, G., Huang, Y., Lv, J., Li, M., Zhao, L., Fan, C., Pu, J., Hou, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23457 · Cited by 12
“In contrast, several subsequent studies found that B7H3 inhibited T cell function [9-12].”
ResultChapoval, A. I., Chapoval, S. P., Shcherbakova, N. S., & Щербаков, Д. Н. (2019) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162019050091 · Cited by 13
Expression patterns of the immune checkpoint ligand CD276 in urothelial carcinoma
Aicher, W. K., Korn, M., Reitnauer, L., Maurer, F. B., Hennenlotter, J., Black, P. C., Todenhöfer, T., Bedke, J., & Stenzl, A. (2021) · BMC Urology · doi:10.1186/s12894-021-00829-0 · Cited by 12
“In another study, CD276 prevented activation of anti-tumor responses by blocking CD4Th1activation [14].”
BackgroundMansorunov, D., Апанович, Н. В., Апанович, П. В., Кипкеева, Ф. М., Музаффарова, Т. А., Kuzevanova, A. Y., Nikulin, M. P., Malikhova, O. A., & Karpukhin, A. V. (2021) · Diagnostics · doi:10.3390/diagnostics11122370 · Cited by 12
“Blocking CD276 binding with antagonistic antibodies significantly increased T-cell proliferation and IL-2 levels [30,31].”
BackgroundZhou, Z., Yu, X., Chen, Y., Tan, X., Liu, W., Hua, W., Chen, L., & Zhang, W. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-03013-4 · Cited by 12
“1 3 and secretion of IFNγ by binding to its receptor on T cells [25].”
BackgroundTherapeutic effects of anti–B7-H3 antibody in an ovalbumin-induced mouse asthma model
Chen, Z., Zhang, G., Wang, Y., Yan, Y., Zhou, W., Zhu, C., Chen, Y., Wang, J., & Ji, W. (2013) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2013.06.030 · Cited by 12
Inhibitors of B7–CD28 Costimulation in Urologic Malignancies
Thompson, R. H., Kwon, E. D., & Allison, J. P. (2008) · Immunotherapy · doi:10.2217/1750743x.1.1.129 · Cited by 15
Overexpression of B7-H3 as an opportunity for targeted therapy in head and neck cancers.
Hu, J., Jiang, C., Zheng, M., Guo, Y.-X., Tang, X., Ren, J. L., Lu, D., Yu, L., Gan, W., Liu, S., et al. (2019) · Europe PMC (PubMed Central) · Cited by 14
Metadata
- Authors
- Suh, W.-K., Gajewska, B. U., Okada, H., Gronski, M. A., Bertram, E. M., Dawicki, W., Duncan, G. S., Bukczynski, J., Plyte, S., Elia, A., Wakeham, A., Itie, A., Chung, S., Da Costa, J., Arya, S., Horan, T., Campbell, P., Gaida, K., Ohashi, P. S., Watts, T. H., Yoshinaga, S. K., Bray, M. R., Jordana, M., & Mak, T. W.
- Affiliations
- University of Toronto (CA)
- McMaster University (CA)
- Amgen (United States) (US)
- Corresponding author
- Suh, Woong-Kyung
- Mak, Tak W
- ORCID
- Venue
- Nature Immunology
- Published
- 2003-08-17
- Volume
- 4
- Issue
- 9
- Pages
- 899-906
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- OpenAlex
- W2052644931
- Cited by
- 576
- References
- 47
- Citations by year
- 2026: 17 · 2025: 39 · 2024: 32 · 2023: 30 · 2022: 37 · 2021: 48 · 2020: 35 · 2019: 29 · 2018: 12 · 2017: 21 · 2016: 20 · 2015: 25 · 2014: 9 · 2013: 18 · 2012: 29
- FWCI
- 7.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- B7-H3, B7 family, T cell proliferation, airway inflammation, interferon-gamma, IL-4, dendritic cells, experimental autoimmune encephalomyelitis, negative regulation of immune response, gene targeting
- MeSH terms
- Animals, Autoantibodies, Dendritic Cells, Encephalomyelitis, Autoimmune, Experimental, Flow Cytometry, Interferon-gamma, Lymphocyte Activation, Lymphocytic choriomeningitis virus, Mice, Inbred C57BL, Orthomyxoviridae, Receptors, Antigen, T-Cell, Vesicular stomatitis Indiana virus, Down-Regulation, Interleukin-4, B7-1 Antigen, Mice, Knockout, Th1 Cells, Mice, B7 Antigens
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.